GlassScriptPhysician profile
Jason Ezequiel Sanchez
NPI 1871826966
$22,939.64
in general payments reported to CMS, 2019-2025
28 companies · $3,962 in 2025
The $3,962 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,010 · 2022: $3,958 · 2023: $8,278 · 2024: $4,732 · 2025: $3,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $3,175 · Education: $229 · Travel and Lodging: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,390.39 |
| Consulting Fee | $3,175.00 |
| Education | $229.49 |
| Travel and Lodging | $177.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,961.59 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $3,393.99 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $2,369.74 | 2021-2025 | Tremfya, Na |
| Incyte Corporation | $1,566.43 | 2021-2025 | Opzelura, Iclusig |
| Genzyme Corporation | $1,308.46 | 2021-2025 | |
| Leo Pharma INC. | $1,093.12 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $1,007.07 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $875.55 | 2021-2025 | Winlevi, Blu-U, Odomzo |
| Ucb, INC. | $779.43 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $773.73 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $669.89 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $661.43 | 2021-2025 | |
| Pfizer INC. | $603.15 | 2021-2024 | |
| Galderma Laboratories, L.P. | $593.03 | 2021-2025 | Nemluvio, Epsolay, Aklief |
| Organogenesis INC. | $552.21 | 2021-2023 | Puraply |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $354.94 | 2023-2024 | Vtama |
| Amgen INC. | $348.16 | 2021-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $266.46 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $225.67 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Vyne Pharmaceuticals INC. | $175.86 | 2021 | |
| Almirall LLC | $133.78 | 2021-2025 | Klisyri, Seysara |
| Botanix Sb INC | $71.12 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $59.45 | 2021-2023 | Valchlor |
| Organon LLC | $37.68 | 2025 | Vtama |
| Abbott Laboratories | $23.61 | 2025 | Freestyle Libre 3 |
| Strata Skin Sciences, INC. | $14.39 | 2025 | Xtrac |
| Epi Health, LLC | $13.08 | 2021 | |
| Biofrontera INC. | $6.62 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.